Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
PureTech Health (PRTC) reported 2025 results and operational updates on April 29, 2026. Key facts: PureTech-level cash and short-term investments were $277.1M at Dec 31, 2025 and $248.1M at Mar 31, 2026; the company states an operational runway through the end of 2028.
Program highlights: Celea's deupirfenidone is Phase 3-ready with orphan designations and a near-complete external fundraising targeting close in early Q3 2026; Gallop and Seaport filed S-1 registration statements for potential IPOs.
PureTech (Nasdaq: PRTC, LSE: PRTC) intends to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading on the London Stock Exchange as its primary venue.
PureTech expects to file Form 25 around May 11, 2026, with Nasdaq ADSs' last trading day on or about May 20, 2026, and plans to pursue Form 15F to suspend and terminate SEC reporting within 90 days if no SEC objection.
Seaport Therapeutics appointed Dr. Sharon Mates to its Board of Directors on April 27, 2026. Dr. Mates co-founded and led Intra-Cellular Therapies through commercialization of CAPLYTA® and its 2025 acquisition by Johnson & Johnson for approximately $14.6 billion. CAPLYTA generated > $1.5 billion in sales prior to that acquisition. Dr. Mates currently serves on the boards of Medincell and Benitec (Nasdaq: BNTC) and will advise Seaport’s neuropsychiatry programs and governance.
PureTech (Nasdaq: PRTC) reported positive topline Phase 1b data for LYT-200 in relapsed/refractory high‑risk MDS and AML on April 22, 2026. Gallop Oncology selected an RP2D (12 mg/kg) and plans FDA discussion toward a potential registration trial in R/R HR‑MDS.
Key metrics: R/R HR‑MDS CR 27.3%, ORR 45.5%, conversion to transplant 18%; R/R AML composite CR 30.8%, ORR 42.3%, conversion to transplant 19.2%. Safety across N=101 showed no LYT‑200 related SAEs, discontinuations, or deaths.
PureTech Health (Nasdaq: PRTC) will publish its Annual Report and financial results for the year ended December 31, 2025 on Wednesday, April 29, 2026.
A presentation and conference call are scheduled for 9:00 AM EDT / 2:00 PM BST that day, with a live webcast available at https://investors.puretechhealth.com/events-presentations.
PureTech (Nasdaq: PRTC) announced publication of Phase 2b ELEVATE IPF results for deupirfenidone 825 mg TID in AJRCCM on April 2, 2026.
Key results: adjusted mean FVC difference +91 mL versus placebo at 26 weeks (p=0.02); HR for IPF progression 0.439 (p=0.0023); ~50% greater exposure versus pirfenidone 801 mg TID with similar overall AE rates.
Celea Therapeutics plans to initiate Phase 3 SURPASS-IPF in H1 2026 pending financing.
Seaport Therapeutics (PRTC Founded Entity) announced positive Phase 1 topline results for GlyphAgo on April 2, 2026.
GlyphAgo achieved a 6.8-fold bioavailability increase versus unmodified agomelatine, reduced PK variability by 10-fold, showed 9.6–14.5x dose-normalized AUC in SAD, was well tolerated in ~130 participants, and triggered plans for Phase 2a and Phase 2b trials.
PureTech (Nasdaq: PRTC) notes that its Founded Entity, Seaport Therapeutics, published first-in-human and preclinical data for GlyphAllo (SPT-300) in Science Translational Medicine on March 25, 2026.
The paper reports GlyphAllo as a triglyceride-mimetic prodrug that enabled oral allopregnanolone bioavailability, dose-dependent therapeutic plasma levels in humans, a significant cortisol reduction in a Phase 2a stress test (p=0.0001), and supported an ongoing global Phase 2b trial initiated July 2025.
PureTech (Nasdaq: PRTC) announced that CEO Robert Lyne and Co-founder/President Eric Elenko, PhD, will speak in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 at 11:20am EDT.
A live webcast will be available via the company's investor site at the scheduled time.
PureTech (Nasdaq: PRTC) announced that the FDA and European Commission granted Orphan Drug Designation to deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF). Phase 2b ELEVATE IPF showed a 91 mL FVC advantage versus placebo at 26 weeks (p=0.02) and a -32.8 mL FVC decline at 52 weeks. Celea Therapeutics plans Phase 3 SURPASS-IPF in H1 2026 and intends to finalize financing in H1 2026 to support initiation.